Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211247 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
A Phase 3 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 414
- Enrollment target
NCT03211247 is a Phase 3 study that has completed, run by DBV Technologies. The registered enrollment target is 414 participants.
The verdict
NCT03211247, a Phase 3 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 414 participants
- Enrollment target
Study Summary
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
Interventions
- BIOLOGICAL Part B Placebo
- BIOLOGICAL Part A Viaskin Peanut 250 mcg
- BIOLOGICAL Part A Viaskin Peanut 100 mcg
- BIOLOGICAL Part A Placebo
- BIOLOGICAL Part B Viaskin Peanut 250 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03211247
The ClinicalTrials.gov registry entry for NCT03211247 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Part B Placebo is the first listed.
NCT03211247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03211247 about?
NCT03211247 is a clinical study titled "Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age". The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
What is the current status of trial NCT03211247?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 414 participants. The study started on 2017-07-31. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03211247?
The interventions under investigation include: Part B Placebo (BIOLOGICAL), Part A Viaskin Peanut 250 mcg (BIOLOGICAL), Part A Viaskin Peanut 100 mcg (BIOLOGICAL), Part A Placebo (BIOLOGICAL), Part B Viaskin Peanut 250 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT03211247?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.